A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Epanova Compared to Placebo and Compared to Fenofibrate on Liver Fat Content in Hypertriglyceridemic overwEight subjeCTs; EFFECT I

Trial Profile

A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Epanova Compared to Placebo and Compared to Fenofibrate on Liver Fat Content in Hypertriglyceridemic overwEight subjeCTs; EFFECT I

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs Eicosapentaenoic acid/docosahexaenoic acid (Primary) ; Fenofibrate
  • Indications Hypertriglyceridaemia
  • Focus Pharmacodynamics
  • Acronyms EFFECT-I
  • Sponsors AstraZeneca
  • Most Recent Events

    • 21 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 29 Feb 2016 Planned End Date changed from 1 Jun 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 29 Feb 2016 Planned primary completion date changed from 1 Jun 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top